Replace Farxiga (Dapagliflozin) with Alternative SGLT2 Inhibitors or GLP-1 Receptor Agonists
When dapagliflozin must be discontinued due to eGFR <25 mL/min/1.73 m², recurrent genital infections, prior ketoacidosis, or drug interactions, switch to empagliflozin (if eGFR ≥20 mL/min/1.73 m²) or a GLP-1 receptor agonist (semaglutide, dulaglutide, or liraglutide) for continued cardiorenal protection. 1
Clinical Decision Algorithm by Contraindication
eGFR <25 mL/min/1.73 m²
Stop dapagliflozin and initiate empagliflozin 10 mg once daily if eGFR ≥20 mL/min/1.73 m², as the 2024 ADA guidelines now support SGLT2 inhibitor use down to eGFR 20 mL/min/1.73 m² for cardiorenal benefit. 12
If eGFR is <20 mL/min/1.73 m², discontinue all SGLT2 inhibitors and switch to a GLP-1 receptor agonist (semaglutide 0.5–1 mg weekly, dulaglutide 0.75–1.5 mg weekly, or liraglutide 0.6–1.8 mg daily), which require no renal dose adjustment and provide cardiovascular protection with lower hypoglycemia risk than insulin. 1
Continue metformin only if eGFR ≥30 mL/min/1.73 m² (maximum 1000 mg/day for eGFR 30–44 mL/min/1.73 m²); discontinue metformin completely if eGFR <30 mL/min/1.73 m². 1
Recurrent Genital Infections
Replace dapagliflozin with a GLP-1 receptor agonist (semaglutide, dulaglutide, or liraglutide), as these agents do not increase genital infection risk and provide equivalent cardiovascular protection. 1
Alternatively, consider the DPP-4 inhibitor linagliptin 5 mg once daily, which requires no renal dose adjustment and has neutral cardiovascular effects with lower hypoglycemia risk than sulfonylureas. 1
Do not substitute another SGLT2 inhibitor (empagliflozin or canagliflozin), as the mechanism-related genital infection risk is a class effect occurring in approximately 6% of patients. 34
Prior Ketoacidosis
Permanently discontinue dapagliflozin and initiate a GLP-1 receptor agonist (semaglutide, dulaglutide, or liraglutide), as SGLT2 inhibitors are contraindicated in patients with a history of diabetic ketoacidosis. 31
If additional glucose lowering is required, add basal insulin (e.g., insulin glargine or degludec) titrated to fasting glucose targets, as insulin remains effective at any eGFR level. 1
Do not use any SGLT2 inhibitor (empagliflozin, canagliflozin, or ertugliflozin) in patients with prior ketoacidosis, as the risk of recurrent euglycemic DKA is a class-wide contraindication. 3
Drug-Drug Interactions
If the interaction involves diuretics causing excessive volume depletion, reduce the diuretic dose by 50% and continue dapagliflozin rather than switching agents, as volume depletion is manageable with dose adjustment. 34
If the interaction involves medications that increase ketoacidosis risk (e.g., very-low-carbohydrate diets, prolonged fasting, or alcohol abuse), discontinue dapagliflozin and switch to a GLP-1 receptor agonist. 1
If the interaction involves nephrotoxic agents (NSAIDs, aminoglycosides, or contrast media), temporarily hold dapagliflozin during the exposure period and resume once renal function stabilizes. 4
Preferred Replacement Agents by Clinical Context
| Clinical Scenario | First-Line Replacement | Dose | Rationale |
|---|---|---|---|
| eGFR 20–24 mL/min/1.73 m² | Empagliflozin | 10 mg once daily | ADA 2024 guidelines support SGLT2 inhibitor use ≥20 mL/min/1.73 m² [1][2] |
| eGFR <20 mL/min/1.73 m² | Semaglutide | 0.5–1 mg weekly SC | No renal dose adjustment; cardiovascular protection [1] |
| Recurrent genital infections | Semaglutide or dulaglutide | 0.5–1 mg weekly SC (semaglutide) or 0.75–1.5 mg weekly SC (dulaglutide) | No genital infection risk; equivalent CV benefit [1] |
| Prior ketoacidosis | Semaglutide + basal insulin | 0.5–1 mg weekly SC + insulin glargine titrated to FPG | SGLT2 inhibitors contraindicated; GLP-1 RA + insulin reduces hypoglycemia [1] |
| Volume depletion risk | Reduce diuretic dose; continue dapagliflozin | 10 mg once daily | Manageable with diuretic adjustment [3][4] |
GLP-1 Receptor Agonist Selection
Semaglutide provides the greatest HbA1c reduction (≈1.5–2.0%) and weight loss (≈6–13 kg), making it the preferred GLP-1 receptor agonist when maximal glycemic and weight benefits are needed. 1
Dulaglutide and liraglutide are appropriate alternatives when semaglutide is unavailable or not tolerated, with similar cardiovascular protection and no renal dose adjustment required. 1
All GLP-1 receptor agonists reduce cardiovascular death or major adverse cardiovascular events by approximately 12–26%, providing robust cardiorenal protection comparable to SGLT2 inhibitors. 1
Critical Safety Monitoring After Switching
Recheck eGFR within 1–2 weeks after stopping dapagliflozin, as the hemodynamic eGFR dip (2–5 mL/min/1.73 m²) will reverse, potentially allowing reinitiation if the contraindication resolves. 4
Monitor glucose closely for the first 2–4 weeks after switching to a GLP-1 receptor agonist, especially if insulin or sulfonylureas remain in the regimen, and reduce those doses by 20–50% to prevent hypoglycemia. 1
Educate patients that GLP-1 receptor agonists cause gastrointestinal side effects (nausea, vomiting, diarrhea) in 20–40% of users, which typically resolve within 4–8 weeks; starting at the lowest dose and titrating slowly minimizes these effects. 1
Common Pitfalls to Avoid
Do not substitute a sulfonylurea (gliclazide, glipizide, or glimepiride) for dapagliflozin, as sulfonylureas provide no cardiovascular or renal protection and increase hypoglycemia risk. 1
Do not discontinue metformin when switching from dapagliflozin to a GLP-1 receptor agonist if eGFR ≥30 mL/min/1.73 m², as metformin remains first-line therapy and provides additive glycemic benefit. 1
Do not combine a GLP-1 receptor agonist with a DPP-4 inhibitor (linagliptin, sitagliptin), as the combination provides no additional clinical benefit and is not recommended. 1
Do not withhold ACE inhibitors or ARBs when switching from dapagliflozin to a GLP-1 receptor agonist, as renin-angiotensin system blockade should be continued for renal protection. 1